Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

Ekso Bionics Stock Down 2.8 %

Shares of EKSO opened at $1.39 on Thursday. The firm has a market capitalization of $19.78 million, a P/E ratio of -1.24 and a beta of 1.65. Ekso Bionics has a 12-month low of $0.62 and a 12-month high of $1.88. The company has a current ratio of 2.85, a quick ratio of 2.15 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $0.90 and a 200-day moving average price of $1.15.

Hedge Funds Weigh In On Ekso Bionics

Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC boosted its stake in shares of Ekso Bionics by 153.4% during the second quarter. Renaissance Technologies LLC now owns 44,606 shares of the company’s stock valued at $74,000 after purchasing an additional 27,006 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Ekso Bionics during the third quarter valued at approximately $28,000. Finally, Strategic Wealth Investment Group LLC boosted its stake in shares of Ekso Bionics by 25.8% during the third quarter. Strategic Wealth Investment Group LLC now owns 42,665 shares of the company’s stock valued at $31,000 after purchasing an additional 8,752 shares in the last quarter. 9.54% of the stock is currently owned by institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.